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Defects in mitochondrial proton-translocating NADH-quinone oxidoreductase (complex I) have been implicated in a number of
acquired and hereditary diseases including Leigh’s syndrome and more recently Parkinson’s disease. A limited number of strategies
have been attempted to repair the damaged complex I with little or no success. We have recently shown that the non-proton-
pumping, internal NADH-ubiquinone oxidoreductase (Ndi1) from Saccharomyces cerevisiae (baker’s yeast) can be successfully
inserted into the mitochondria of mice and rats, and the enzyme was found to be fully active. Using recombinant adenoassociated
virusvectors(serotype5)carryingourNDI1gene,wewereabletoexpresstheNdi1proteininthesubstantianigra(SN)ofC57BL/6
mice with an expression period of two months. The results show that the AAV serotype 5 was highly eﬃcient in expressing Ndi1
in the SN, when compared to a previous model using serotype 2, which led to nearly 100% protection when using an acute
MPTP model. It is conceivable that the AAV-serotype5 carrying the NDI1 gene is a powerful tool for proof-of-concept study to
demonstrate complex I defects as the causable factor in diseases of the brain.
1.Introduction
Parkinson’s disease (PD), the second most common neu-
rodegenerative disorder, is characterized by a loss of
dopaminergic neurons in the substantia nigra (SN) which
leads to a decrease in dopamine levels and a loss of motor
control. The challenge in treating PD stems from a lack of
understanding with regard to what triggers the onset of the
disease. Studies of the disease through human pathology or
from toxin-induced models, speciﬁcally 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP), have identiﬁed three
possible sources; oxidative stress, mitochondrial defects, and
abnormal aggregation of proteins [1–4], and in some rare
cases, inherited genetic defects. The discovery of MPTP as
a neurotoxin has given neuroscientists the ability to develop
animal models, mostly in mice and nonhuman primates, to
investigate the mechanism(s) that may lead to PD in humans
[5, 6]. Current evaluation strategies involve the testing
of animal models through neurochemical analysis (HPLC,
western blots, and immunohistochemistry) and behavioral
assessment [7–9].
The use of recombinant-associated adeno virus (rAAV)
has been widely explored as a gene therapy tool for the
past 20 years [10]. Through extensive research, a number
of serotypes have been isolated (AAV1-11) and engineered,
with each showing diﬀering selectivity and eﬃciency at
infecting tissues ranging from the CNS (neurons) to skeletal
muscles [11]. The most common serotypes that are used for
gene delivery in the CNS include serotypes 2 and 5 with
serotype 2 being the most widely used thus far. The goals of
current gene therapy models include promoting cell survival
or modiﬁcation of activity in the damaged region [12].
Some of the gene therapies attempted to date include glial
cell line-derived neurotrophic factor (GDNF) and enzymes2 Parkinson’s Disease
involved in dopamine synthesis (tyrosine hydroxylase (TH)
and aromatic acid decarboxylase (AADC)) with limited
success [12, 13]. More recently, a preliminary report on a
clinicaltrialinhumanswaspublishedindicating thesafetyof
using AAV as a vehicle to introduce genes into the brain [14].
In addition, they were able to demonstrate an improvement
in the patients with the use of a gene that regulates the level
of GABA in the basal ganglia [14]. This initial study provides
great potential for further studies and the use of other genes
to modify signaling in the brain as a treatment for PD and
other neurodegenerative diseases.
As mentioned above, one of the possible triggers of
Parkinson’s disease may involve defects in the mitochondrial
respiratory chain. Therefore, our approach involves a gene
therapytocomplementthedamagedmitochondria usingthe
internal NADH-ubiquinone oxidoreductase derived from
Saccharomyces cerevisiae (baker’s yeast), NDI1 [15–20]. The
NDI1 gene will be expressed in the SN of mice using rAAV
serotype5,asacomparisontoapreviousstudywiththisgene
using rAAV serotype 2. In addition to immunohistochemical
data, behavioral testing will be used to evaluate the ability of
NDI1 to protect against the toxic eﬀects of MPTP.
2.MaterialsandMethods
2.1. Animals. Twelve-week-old male (25–30g) C57Bl/6 mice
(obtained from our in-house breeding colony) were housed
four per cage in a temperature-controlled environment
under 12-hr light/dark cycle with free access to food and
water. The housing and treatment of the animals was
conducted in accordance with the National Institutes of
Health Guide for the Care and Use of Laboratory Animals,
andtheInstitutionalAnimalCareandUseCommitteeatThe
Scripps Research Institute approved all procedures.
2.2. Injection of AAV-NDI1. Recombinant AAV serotype
5 (rAAV5) carrying the NDI1 gene (designated rAAV5-
NDI1) was produced by and purchased from Applied
Viromics (Fremont, CA). The ﬁnal viral particle concen-
tration, estimated by dot blot assay, was determined to
be 3.1 × 1012 viral particles/ml. Surgical procedures were
performed as previously described by Seo et al. [19].
Brieﬂy, anesthesia was induced with 3% of isoﬂurane in
O2, and mice were secured in a stereotaxic frame (Kopf
Instruments, Tujunga, CA). Anesthesia was maintained for
the duration of the surgical procedure with 1.5–2% of
isoﬂurane in O2 through a nose tip ﬁxed to the stereotaxic
frame. All rAAV5-NDI1 injections were made using a 5-
µL Hamilton microsyringe with a 30-gauge beveled needle.
A single injection of 2µL rAAV5-NDI1 (suspended in PBS
containing 0.1% of ﬂuorescent beads) was made in the
right hemisphere at the following coordinates (measured
from bregma/dura): AP: −3.3mm, ML: 1.5mm, and DL:
−3.9mm, at a rate of 0.2µL/min. Expression levels were
veriﬁed two months after injection, and prior to any drug
treatment.
2.3. MPTP Treatment. MPTP handling and safety measures
wereinaccordancewiththechemicalhygieneplandeveloped
at The Scripps Research Institute. Approximately 2 months
aftertherAAV5-NDI1injection,miceweresubjectedtoacute
MPTP treatment, as reported by Seo et al. [19]. Brieﬂy,
MPTP (in sterile saline) was administered intraperitoneally
at a dose of 15mg/kg of body weight. A total of 4 injections
were performed at 2-hour intervals with a 100% survival
rate. The MPTP-treated groups were divided into either
NDI1+MPTP (n = 14) or MPTP only (n = 8). Control
animals (NDI1+Saline, n = 10) were injected with the
vehicle (sterile saline) in place of the MPTP solution.
2.4. Behavioral Testing. Behavioral testing was performed
as described previously by Baber-Singh et al. [7]. One
week prior to and 1-week post-MPTP treatment animals
were tested using the elevated body swing (EBS) [7, 21,
22] and methamphetamine- (MA-) induced rotation tests.
EBS and MA-induced rotation trials were videotaped and
analyzed at a later time by an unbiased observer. For the
EBS test, each animal was held 1cm from the base of
the tail and suspended approximately 1cm above the table
for 60sec. Movements greater than 30◦ from vertical were
counted as a swing, and the next swing was counted only
after the animal returned to or passed through the neutral
position.
Prior to the administration of MA (1.5mg/kg), animals
were allowed 5min to acclimate to the bowl environment.
Evaluation of activity was initiated 15min after the admin-
istration of MA, to allow for the drug to take eﬀect, and
then continuously for 40min. The number of quarter turns
around the bowl was used to evaluate any bias created by
the protection of NDI1 when challenged with MPTP or
saline.
2.5. HPLC Analysis. One-half of the mice from each treat-
mentgroupwereeuthanizedforHPLCanalysisofstriatalDA
and its metabolite levels [19, 23]. The mice were perfused
with saline, after which brains were quickly removed and
frozen on dry ice, and maintained at −80◦C until chemical
analysis was performed. The method used was similar to that
outlined by Seo et al. [19]. Brains were dissected with a razor
blade to approximately 2mm thick sections. Striatal regions
from each side of the brain were isolated separately and
weighed. Each sample was homogenized by sonication in 5
volumes of ice-cold 0.2M perchloric acid and deproteinized
by centrifugation at 14,000rpm for 15min at 4◦C. Aromatic
amines and their metabolites were separated using ion-
paired reversed phase HPLC coupled with electrochemical
detection (Eicom ECD-300, Kyoto, Japan). Samples (6µL)
kept on ice were injected into the HPLC system equipped
with an SC-3ODS column (3µm, 3 × 100mm; Eicom) with
a ﬂow rate of 4ml/min, at room temperature. The mobile
phase was composed of 0.1M citrate-acetate buﬀer, 1mM
sodium octane sulfate, and 13µM EDTA·2Na with a ﬁnal
pH adjusted to 3.5 prior to adding 20% (v/v) of methanol.
The analytes were detected on a graphite-working electrode
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were collected using an EPC-500 processor (Eicom); peakParkinson’s Disease 3
areas were calculated using the PowerChrom software and
quantiﬁed from a calibration curve of standards.
2.6. Immunohistochemistry. The remaining mice from each
group were perfused with saline followed by cold 4% (w/v)
paraformaldehyde solution. The brains were removed and
postﬁxed in the paraformaldehyde solution for 1hr at 4◦C.
Brains were frozen in OCT compound (Sakura, Torrance,
CA) and stored at −20◦C until further processing. 30-µm
sections were collected using a cryostat (Microm, Germany),
directlymountedontoslides,andstoredat −20◦C.Immuno-
histochemistry using antibodies against NDI1 (1:250, pre-
pared in our laboratory), tyrosine hydroxylase (TH, 1:500,
EMD Bioscience/Calbiochem, La Jolla, CA), and glial ﬁbril-
lary acidic protein (GFAP, 1:250, Sigma-Aldrich, St. Louis,
MO)wascarriedoutonslidesectionsaspreviouslydescribed
by Seo et al. [19]. Brieﬂy, each section was ﬁrst rinsed in
PBS, followed by incubation in a 3% hydrogen peroxide
solution for 30min to quench native peroxidases, followed
by permeabilization and blocking for nonspeciﬁc binding
with 10% goat serum, 5% horse serum, and 0.1% Triton
X-100/PBS at room temperature for 1hr. Sections were
then incubated with primary antibody overnight at 4◦C.
For TH and GFAP, sections were subsequently incubated
with biotinylated secondary antibody for 1hr at room
temperature followed by revelation with the ABC elite kit
(Vector Laboratories, Burlingame, CA) and DAB (3,3 -
diaminobenzidine tetrachloride, Sigma-Aldrich, St. Louis,
MO). NDI1 protein staining was done using the tyramide
signal ampliﬁcation following the manufacturer’s procedure
(PerkinElmer, Boston, MA). The sections were blocked using
Image-iT FX (Molecular Probes, Eugene, OR), followed
by primary antibody overnight at 4◦C, and horseradish
peroxidase-conjugated goat antirabbit IgG (1:1000, EMD
Bioscience/Calbiochem) at room temperature for 2hrs. The
sections were then rinsed 3 times in PBS for 10min and
then incubated with the ﬂuorophore tyramide ampliﬁcation
solution (1:75, dilution with ampliﬁcation buﬀer) for 7min
at room temperature followed by rinsing in PBS.
2.7. NADH Activity Staining. Histochemical staining for
NADH dehydrogenase activity was based on the NADH-
tetrazolium reductase reaction [19]. Brain sections were
incubated with an NADH-tetrazolium reductase solution
(0.2M Tris-Cl, pH 7.4, 1.5mM NADH, and 1.5mM nitro
blue tetrazolium) at room temperature until sections were
overstained (t>10min, bright purple), followed by removal
ofexcesscolorinaseriesofacetonesolutions(30%,60%,and
90%) for 1min each, and rinsed 3 times 10min in deionized
water.
2.8. Western Blotting. Samples used for HPLC analysis were
further processed for Western blotting using a protocol
outlined in Barber-Singh et al. [7]. Samples were thoroughly
mixed and neutralized with 1M Tris (pH 11), after which
2µL of DNase (50mg/ml, Roche, Indianapolis, IN) was
added, along with a protease inhibitor cocktail (Complete
Mini, Roche) containing 1mM EDTA. To this, SDS at a
ﬁnal concentration of 5% was added, and the samples were
incubated at room temperature for 1hr prior to protein
evaluation in each sample using the Bradford method.
Samples were diluted in 2 × sample buﬀer to a ﬁnal
concentration of 4µg/µL. Sixty micrograms of total protein
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gel then transferred to a 0.22-µm nitrocellulose membrane
(Scleicher and Schueller, Germany). Detection was per-
formed using the following antibodies: monoclonal mouse
anti-TH 1:1000 (EMD Bioscience/Calbiochem), polyclonal
rabbit anti-VMAT2 1:1000 (Chemicon, Temecula, CA),
monoclonal rat-anti-DAT 1:5000 (Chemicon), monoclonal
mouse anti-GAPDH 1:2000 (Chemicon), and rat-anti-
NDI1 1:5000 (prepared in our laboratory) [24]. Visualiza-
tion of the protein bands was accomplished using the appro-
priate secondary, either goat antimouse horseradish peroxi-
dase (HRP) (1:1000, Pierce), antirabbit HRP (1:5000, GE
Healthcare, United Kingdom), or antirat HRP (1:10,000,
Chemicon) followed by revelation with SuperSignal West
Pico chemiluminescence kit (Pierce, Rockford, IL). Chemi-
luminescence signals were collected on autoradiography ﬁlm
and the density of each band was measured using the ImageJ
software [25].
2.9. Statistical Analysis. Statistical analysis was performed
using the Student’s t-test. Results are expressed as the mean
± standard error of the mean (SEM). Statistical analysis of
stainingdensitywascollectedandevaluatedusingtheImageJ
software. Threshold values were set for the entire group of
subjects, for example, GFAP or TH staining and applied
to all sections prior to evaluating density values. Statistical
signiﬁcance was set as follows, unless indicated elsewhere:
∗∗ if P<. 01, ∗∗∗ if P<. 001.
3. Results
3.1. Expression of the NDI1 Protein in the Mouse SN. An
important aspect of gene therapy is the ability to target
the appropriate structure in vivo and to have widespread
expression of protein in the desired region without inter-
fering in the native function of surrounding regions. It
is therefore crucial to verify the location and extent of
NDI1 protein expression in the substantia nigra (Figures
1(a) and 1(b)). The AAV-NDI1 serotype 5 that was chosen
for use in this experiment shows high levels of expression
throughout the SN (Figure 1(a)), when compared to TH
levels (Figure 1(b)). In addition, NADH activity staining
reveals widespread NDI1 expression throughout much of the
SN in serial sections, averaging 900µm in both the saline
and MPTP-treated groups (Figures 2(a)–2(d)). In contrast,
previous trials using AAV-NDI1 serotype 2 showed that the
expression of NDI1 was predominantly limited to regions
near the injection point (Figure 1(c)) when compared to TH
levels (Figure 1(d)). Also, the spread (anterior-posterior) of
virus throughout the SN was limited, typically 300–450µm
measured by the number of NDI1-positive sections. This
ranges from 10 to 15 sections depending on the placement
of the injection, as the time for expression was equal4 Parkinson’s Disease
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Figure 1: Comparison of NDI1 expression levels in the SN
when using AAV serotype 5 versus serotype 2. All images were
obtained approximately 2 months after injection of AAV-NDI1 in
control mice. (a) NDI1 expression after injection of rAAV5-NDI1,
(b) TH levels in SN corresponding to (a). (c) NDI1 expression
after injection of AAV-NDI1 serotype 2, (d) TH levels in SN
correspondingto(c).Scalebar=200µmfor(a)and(b),and200µm
for (c) and (d).
for both serotypes. The increase in NDI1 expression, for
serotype 5, is further established with the behavioral and
immunochemical data represented below.
3.2. Eﬀect of NDI1 Expression on Behavior Following either
Saline or MPTP Treatment. The elevated body swing test
(Figure 3(a)) was chosen due to the fact that it is a nondrug-
based test for lateralized activity in unilateral Parkinson’s
models. It has been reported that the eﬀect of administering
amphetamines multiple times can lead to a sensitization
resulting in poor correlation between neuronal loss and
No NDI1 NDI1 transduced
(a)
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Figure 2: Representative SN images from the NDI1 + Saline
group demonstrating the spread of functional NDI1 2 months
after injection. Expression of NDI1 was revealed by NADH activity
staining. Image position is given relative to the injection point,
whichwasdeterminedbythepresenceofﬂuorescentbeadsaddedto
rAAV solution prior to injection. (a) ∼150µm anterior of injection
point, (b) point of injection, (c) ∼180µm posterior of (b), and
(d) ∼720µm posterior of (b). Arrows indicate the SN.
behavioral eﬀects. Each group of animals was ﬁrst tested 1
week prior to and again approximately 1 week after MPTP
treatmenttoevaluatetheprotectiveeﬀectofNDI1expression
in the nigrostriatal pathway. In the pre-MPTP trials, the
results conﬁrmed no bias towards one side or the other (data
not shown). The % left and % right swings were as follows
(mean ± SEM): MPTP Only (MO) = 52.5% (± 2.6, L) and
47.5%(±2.6,R);NDI1+Saline(NS) =47.5%(±2.8,L)and
52.5% (± 2.8, R); NDI1 + MPTP (NM) = 48.4% (± 2.1, L)
and 51.6% (± 2.1, R). Analysis of the post-MPTP treatmentParkinson’s Disease 5
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Figure 3: Analysis of mouse behavior tests 1 week after MPTP
treatment. All trials were videotaped and analyzed at a later time
by an observer blind to the identity of the animal. (a) For the
EBS test, each animal was held 1cm from the base of its tail
and suspended approximately 1cm above the table for 60sec. The
number of swings greater than 30◦ from the vertical position was
counted, and the next swing was counted only after the animal
passed through vertical. (b) For the drug-induced rotation test, the
number of quarter turns around the bowl and the direction were
used to evaluate any bias created by the protection of NDI1 when
challenged with either MPTP or saline. Data are represented as
mean ± SEM (MPTP Only, n = 8; NDI1 + Saline, n = 10; NDI1 +
MPTP, n = 14) ∗∗∗ = P< . 0005. Light grey column, movement
left; dark grey column, movement right.
revealed a signiﬁcant change in behavior for the NM group
only (Figure 3(a)), to 67.9% (± 3.4, L) and 32.1% (± 3.4, R).
Methamphetamine- (MA-) induced rotation provides
a robust method for evaluating unilateral damage in the
Parkinson’s mouse model. One week prior to and 1 week
after MPTP treatment, animals were injected with 1.5mg/kg
MA. Rotational behavior (Figure 3(b)) was monitored for
40min, with no signiﬁcant bias for the pre-MPTP treatment
test (results not shown). The % turns were as follows
(mean±SEM):MO=47.4%(±7.1,L)and52.6%(±7.1,R),
NS = 52.4% (± 5.1, L) and 46.6% (± 5.1, R), and NM =
55.0%(±4.0,L)and45.0%(±4.0,R).OneweekafterMPTP
treatment, the test was repeated (total time between trials
was 3 weeks), which resulted in a signiﬁcant bias for the NM
grouponly(Figure3(b)),76.8%(±3.1,L)and23.2%(±3.1,
R).
3.3. Neurochemical Analysis of the Dopaminergic System. To
evaluate the level of protection that expression of NDI1
provided to the nigrostriatal system, HPLC analysis of the
striatal region was used to evaluate the levels of DA, DOPAC,
and serotonin (Figures 4(a)–4(c)). Signiﬁcant decreases were
observed for the MPTP-Only (MO) group, to approximately
30%ofcontrol(NS)forDA(Figure4(a))and75%ofcontrol
for DOPAC (Figure 4(b)), as well as the nontransduced
hemisphere for the NDI1-MPTP (NM), 32% of control
for DA, (Figure 4(a)) and 73% of control for DOPAC
(Figure 4(b)). For the NDI1-transduced hemisphere 100%
protection was observed for both DA (Figure 4(a)) and the
m a j o rD Am e t a b o l i t eD O P A C( F i g u r e4(b)). As expected,
there were no signiﬁcant changes in the serotonin levels with
the administration of MPTP (Figure 4(c)).
Following HPLC measurements, samples were further
prepared for Western blotting analysis of the two dopamin-
ergictransporters,VMAT2andDAT, aswellasTHandNDI1
levels after MPTP treatment (Figure 5(a)). When compared
to the control group (NS), both the MO group and the
nontransduced side of the NM group showed signiﬁcant
decreases in all proteins, with TH levels falling below the
limit of detection. Statistical analysis of the Western blots
for each protein further shows that the NDI1-transduced
hemisphere provided protection against MPTP, with levels
similar to that of the control group (NS) (Figure 5(b)).
3.4. Immunohistochemical Assessment of Neurodegeneration
following MPTP Treatment. In order to determine function-
ality of the NDI1 protein, sections were incubated with
NADH and tetrazolium as the substrates (Figure 6(a)).
Darker blue staining in the SN and CPu (right hemisphere,
white arrow) corresponds to the regions of functional NDI1
expression, and lighter blue/purple staining in the opposite
hemisphere is presumably due to native complex I activity.
Both the MO and the NM groups clearly have weaker NADH
activity in the left hemisphere in both the SN and CPu when
compared to the saline-treated group (Figure 6(a)).
In addition, to assess the degree of protection provided
to the nigrostriatal system by NDI1 expression, serial striatal
sections were analyzed using two immunohistochemical
markers, GFAP and TH (Figure 6(b)). The GFAP staining
clearly shows increased damage in the MO group, in both
hemispheres, and in the nontransduced hemisphere of the
NM group. Comparable results were observed for the TH
staining, with a signiﬁcant diﬀerence in staining between
the nontransduced and NDI1-transduced hemispheres, as
well as a signiﬁcant decrease in TH staining for the MO
group when compared to control. Statistical analysis of all
tissue stained for GFAP and TH (Figures 7(a) and 7(b))
further conﬁrms the signiﬁcant diﬀerences between MO6 Parkinson’s Disease
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Figure 4: Measurement of aromatic amine levels in the mouse striatum 2 weeks after MPTP treatment. One-half of the animals from each
group were euthanized, and brains were immediately frozen on dry ice prior to HPLC analysis. Striatal sections from each hemisphere were
isolated separately and processed as described in the materials and methods section. (a) Dopamine (DA), (b) DOPAC, the major metabolite
of DA, and (c) Serotonin (5-HT). Results are expressed as mean ± SEM (MPTP Only, n = 5; NDI1 + Saline, n = 5; NDI1 + MPTP, n = 7)
∗∗∗ = P< . 0001. Light grey column, left hemisphere; dark gray column, right hemisphere.
and NS as well as the signiﬁcant diﬀerence between the
hemispheres of the NM hemispheres. For the MO group,
the GFAP (Figure 7(a)) staining was more than 150% of NS
levels, and the nontransduced hemisphere of the NM group
was also 150% of saline-treated animals. For TH staining
(Figure 7(b)), MO animals had a 60% reduction in TH
levels compared to saline-treated animals. In addition, the
NM group had nearly a 90% reduction in TH staining in
the nontransduced hemisphere and a slight decrease (not
signiﬁcant) in the TH staining in the NDI1-transduced
hemisphere.
4. Discussion
The use of gene therapy for the treatment of Parkinson’s
disease has become more widespread in recent years with
a focus on introducing neurotrophic factors and enzymes
responsiblefortheproductionofneurotransmitters(e.g.,DA
andGABA)asameanstopreventfurtherlossofneurons[12,
13, 26]. These remedies are most commonly introduced into
the appropriate brain region using recombinant adenoasso-
ciated viruses (rAAVs). The most commonly used serotype
in gene therapy applications, using rAAV, has been type 2
which has been shown to transduce neurons in a number
of brain regions, including the substantia nigra (SN) [10,
11, 26]. However, further research has produced additional
recombinantserotypesthatdemonstratehighertransduction
eﬃciency for speciﬁc brain regions. For example, serotype
5 was shown to be highly speciﬁc for the SN [10]. This has
beenconﬁrmedwiththediﬀerencein NDI1expression levels
found in the SN 2 months after injection, for serotype 2
(low) versus 5 (high). The level of expression strongly cor-
relates with the protection provided, as evidenced through
neurochemical analysis. Previous trials using rAAV2-NDI1
found 60% retention of DA levels in the striatum after acute
MPTP treatment [19]. In contrast, the results here revealedParkinson’s Disease 7
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Figure 5: Evaluation of MPTP eﬀects on the DAergic neurons of the striatum using mouse brain homogenates. (a) Representative Western
blots, 60µg of protein per lane was loaded on a 10% SDS-PAGE gel, (b) statistical analysis of western blots for each treatment group MPTP
Only (MO), NDI1 + Saline (NS), and NDI1 + MPTP (NM), VMAT2 (n = 7,7,10), DAT (n = 8,8,11), TH (n = 5,5,7), and NDI1
(n = 0,9,13). ∗∗ = P<. 005, ∗∗∗ = P<. 00001. Light grey column, left hemisphere; dark grey column, right hemisphere.
that stronger and more widespread expression can result in
100% retention of DA levels in an acute MPTP model, when
compared to controls.
Behavioral analysis of our MPTP model revealed later-
alization of movement in the NM group only, for both the
elevatedbodyswing(EBST)anddrug-inducedrotationtests.
For the methamphetamine-induced rotation, as expected,
the animals rotated towards the lesioned side. The source
of ipsilateral rotation has been described in a number of
papers regarding the unilateral depletion of dopamine in the8 Parkinson’s Disease
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Figure 6: Functional expression of NDI1 in the SN and CPu and protective eﬀects following treatment with either saline or MPTP. Two
weeks after the last injection, one-half of the mice were sacriﬁced for immunohistochemical analysis. (a) Representative NADH activity
staining in the SN and CPu for each treatment group. Arrows in SN indicate the substantia nigra. Arrows in CPu indicate the injection side.
(b) GFAP and TH levels in CPu.
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Figure 7: Statistical analysis of GFAP and TH staining density in the mouse striatum: a comparison between left and right hemisphere
in MO, NS, and NM groups. Images with GFAP (n = 28) and TH (n = 35) immunostaining were collected and processed using the
ImageJ software. (a) Density measurement of GFAP staining was evaluated for each hemisphere and compared to control (NDI1 + Saline,
n = 10), results given as % control ± SEM (MPTP Only, n = 6; NDI1 +M P T P ,n = 12). (b) The same procedure was used to evaluate
TH density of each hemisphere, reported as % control ± SEM. (MPTP Only, n = 8; NDI1 + Saline, n = 12; NDI1 +M P T P ,n = 15)
∗∗ = P<. 005,∗∗∗ = P<. 0001. Light grey column, left hemisphere; dark grey column, right hemisphere.
nigrostriatalsystem[22,27,28].Theelevatedbodyswingtest
(EBS) has been used extensively with the unilateral 6-OHDA
rat and mouse models [21, 22, 27, 29] and previously
described for MPTP-treated mice by our group in a chronic
MPTP study [7]. The results for the EBS test exhibited good
correlation with the drug-induced rotation test, movement
towards the lesioned side for the NM group (ipsilateral),
and with a previous test in a chronic MPTP mouse model
[7]. Similar tests in a 6-OHDA Parkinson model showed
either a contralateral movement or no eﬀect [21, 22, 29].
However, an interesting result published by Abrous et al.
[27] demonstrated that this test may be dependent on a few
factors. First, being the extent of the lesion, and second, the
length of time after treatment that the test is administered;
both of which may aﬀect the changes in activity over long
periods of time (i.e., months). However, in our chronic
MPTP Parkinson model, we achieved the same outcome as
in this experiment when testing animals more than 3 weekParkinson’s Disease 9
after treatment [7]. And as demonstrated both in the acute
and chronic models through immunohistochemical analysis,
the MPTP-treated animals have extensive loss of nigrostriatal
neurons, resulting in ipsilateral movement in the NDI1-
transduced + MPTP-treated group.
An immunohistochemical hallmark of MPTP treatment
is the loss of TH-positive neurons in both the SN and CPu
[8, 30]. This result was clearly observed in the MO group,
as well as signiﬁcant loss on the non-NDI1 side of the NM
group. In addition, a signiﬁcant increase in GFAP staining
corresponded well with the loss of TH in both the SN and
CPu. Again, the presence of NDI1 in both the SN and CPu
shows a protective eﬀect when challenged with an acute
MPTP treatment, and all immunohistochemical results were
supported by the Western blot analysis. As was expected, the
amount of both monoamine transporter proteins, in non-
NDI1 samples, in the CPu was decreased when compared
to controls as well as the levels of TH after 2 weeks. This
marked decrease in monoamine transporters is expected
as they are the primary route of MPP+ sequestration and
consequent toxicity in the brain [6, 31–33]. In addition, once
MPP+ has entered the neuron, there is a passive transport
into the mitochondria resulting in inhibition of complex I
activity and possibly the overproduction of reactive oxygen
species (ROS) [3, 34–37]. The presence of NDI1 in the NM
group has prevented the deleterious eﬀects of MPP+ in the
neuron which resulted in transporter levels that were not
signiﬁcantly altered compared to controls and only a slight
decrease in TH levels.
5. Conclusion
In conclusion, all results obtained demonstrate a clear
protective eﬀect of NDI1 in the dopaminergic system. The
use of serotype 5 in the dopaminergic neurons resulted
in greater expression eﬃciency and consequently better
protection when challenged with MPTP in an acute PD
mouse model. The use of behavioral testing in conjunction
with neurochemical analysis provided a more complete
evaluation of the unilateral MPTP PD model. These results
providefurthersupportfortheuseofNDI1asagenetherapy
for the treatment of PD and the possibility for use in other
mitochondrial complex I-deﬁcient diseases.
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